Robeco Institutional Asset Management B.V. Invests $2.26 Million in Organon & Co. (NYSE:OGN)

Robeco Institutional Asset Management B.V. acquired a new position in shares of Organon & Co. (NYSE:OGN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 151,660 shares of the company’s stock, valued at approximately $2,263,000. Robeco Institutional Asset Management B.V. owned 0.06% of Organon & Co. as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Prospera Private Wealth LLC bought a new position in shares of Organon & Co. in the third quarter valued at approximately $25,000. Horizon Bancorp Inc. IN lifted its stake in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after acquiring an additional 1,585 shares in the last quarter. Abich Financial Wealth Management LLC grew its stake in shares of Organon & Co. by 5,646.3% in the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after acquiring an additional 2,315 shares in the last quarter. Trust Co. of Vermont raised its holdings in shares of Organon & Co. by 109.4% in the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after purchasing an additional 1,372 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after purchasing an additional 672 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Organon & Co. currently has a consensus rating of “Hold” and a consensus target price of $21.33.

Organon & Co. Stock Performance

NYSE:OGN opened at $14.94 on Tuesday. The company has a market capitalization of $3.85 billion, a P/E ratio of 2.96, a P/E/G ratio of 0.87 and a beta of 0.76. The business has a fifty day simple moving average of $15.44 and a two-hundred day simple moving average of $17.85. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.